Retatrutide

Weight Management Research

$50.00

5mg vial

What it does

Investigational triple agonist (GLP-1/GIP/glucagon). Phase 2 trials showed up to ~24% body weight loss — currently one of the most effective weight loss agents in development. Improves A1C, lipids, and cardiometabolic health.

Select size · 5mg

Research advisory

RESEARCH / LABORATORY USE ONLY. Not approved for human use. Dose-dependent GI side effects (nausea, vomiting, diarrhea). Heart rate increase possible. Rapid weight loss can cause muscle loss — pair with resistance training + 1.6-2.2g protein/kg. Long-term safety data still limited (Phase 3 ongoing).

COA available

Cold chain

Research only

Research highlights

Investigational triple agonist (GLP-1 / GIP / glucagon)

Phase 2 trials showed up to ~24% body weight loss - currently one of the most effective weight loss agents in development

Improves A1C, lipids, and cardiometabolic health